Drug profile · INN
torsemide
TORSEMIDE
torsemide (TORSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
Drug details — torsemide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 0
- Data quality
- 0.89
Quick answer
torsemide (TORSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium-(potassium)-chloride cotransporter 2 inhibitor
Primary target: Solute carrier family 12 member 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is torsemide?
torsemide (TORSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
What is the brand name for torsemide?
TORSEMIDE is a marketed brand name for torsemide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of torsemide?
torsemide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.